GLP1R and neoplasm: Alternatively, targeting tumor-associated macrophages could be explored to abrogate the negative effects of GLP-1 targeting agents.34 In conclusion, this study unveils a critical clinical scenario that may significantly impact survival outcomes in an aggressive cancer, highlighting the imperative to more carefully assess how metabolic therapies impinge on cancer treatments.